Efficacy and safety of intravenous bevacizumab on severe bleeding associated with hemorrhagic hereditary telangiectasia: A national, randomized multicenter trial

• Published in: Journal of internal medicine Vol. 294; no. 6; pp. 761 - 774
• Main Authors: Dupuis-Girod, Sophie, Rivière, Sophie, Lavigne, Christian, Fargeton, Anne-Emmanuelle, Gilbert-Dussardier, Brigitte, Grobost, Vincent, Leguy-Seguin, Vanessa, Maillard, Hélène, Mohamed, Shirine, Decullier, Evelyne, Roux, Adeline, Bernard, Lorraine, Saurin, Jean-Christophe, Saroul, Nicolas, Faure, Frédéric, Cartier, Cesar, Altwegg, Romain, Laccourreye, Laurent, Oberti, Frédéric, Beaudoin, Marjolaine, Dhelens, Carole, Desvignes, Céline, Azzopardi, Nicolas, Paintaud, Gilles, Hermann, Ruben, Chinet, Thierry
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.12.2023; Wiley
• Subjects: Adult; Antibodies, Monoclonal, Humanized - adverse effects; Bevacizumab; Bevacizumab - adverse effects; Blood; Blood transfusion; Double-Blind Method; Effectiveness; Erythrocytes; Genetics; Hemoglobin; Hemorrhage; Hemorrhage - drug therapy; Hereditary hemorrhagic telangiectasia; Human genetics; Humans; Life Sciences; Middle Aged; Monoclonal antibodies; Pharmaceutical sciences; Pharmacokinetics; Pharmacology; Placebos; Telangiectasia, Hereditary Hemorrhagic - complications; Telangiectasia, Hereditary Hemorrhagic - drug therapy; Treatment Outcome; bevacizumab; rare vascular disease; hereditary hemorrhagic telangiectasia; red blood cell transfusion
• ISSN: 0954-6820; 1365-2796; 1365-2796
• DOI: 10.1111/joim.13714

Bevacizumab-a humanized monoclonal antibody-has been widely used to treat patients with hereditary hemorrhagic telangiectasia (HHT), but no randomized trial has yet been conducted. This study is a double-blind multicenter randomized phase 2 trial with a 1:1 active-treatment-to-placebo ratio. We included patients over the age of 18 with a confirmed diagnosis and the need for at least four red blood cell (RBC) units transfused in the 3 months before study enrollment. Bevacizumab was administered at a dose of 5 mg/kg every 14 days with a total of six injections. The primary efficacy criterion was a decrease of at least 50% in the cumulative number of RBC units transfused in a 3-month period before and after treatment. A total of 24 patients (12 in each group) were included and randomized at 4 different centers. In intention-to-treat analysis, 63.6% of patients (7/11) in the bevacizumab group versus 33.3% of patients (4/12) in the placebo group decreased the number of blood transfusions by at least 50% (p = 0.22). Hemoglobin levels significantly improved at 6 months in the bevacizumab versus placebo group (p = 0.02). The pharmacokinetics study revealed that patients with high exposure to bevacizumab had a significant decrease in RBC transfusions (p = 0.03). Fifty-nine adverse events were observed, 34 in the placebo arm versus 25 in the bevacizumab arm. Though the present trial was underpowered, patients with HHT receiving bevacizumab required numerically fewer red blood cell transfusions than those receiving placebo, particularly those with high exposure.